Key Highlights
- $7M seed funding round led by J2 Ventures with 8VC and Praxis participation
- Funding to enhance on-demand design and manufacturing for microfluidics
- Launch of MV-2 microvalve, optimized for point-of-care applications
- Accelerates diagnostics, drug discovery, and precision medicine
Source: PR Newswire
Notable Quotes
- “Scientists and engineers developing the next breakthrough life science technology shouldn’t be forced to reinvent the wheel when it comes to microfluidic systems, especially in applications like point-of-care diagnostics.” – Jon Bronson, PhD, Managing Partner at J2 Ventures
- “At Parallel Fluidics, we are on a mission to help scientific teams build scalable and reliable products to identify diseases faster and develop more effective medicines.” – Josh Gomes, CEO at Parallel Fluidics
- “Solutions like Parallel Fluidics’ microfluidic systems are filling that gap with their microvalves and enabling faster, more reliable processes that can help us enhance patient outcomes.” – Lionel Matthys, Chief Product Officer at Overture Life
SoHC's Take
Parallel Fluidics is at the forefront of transforming life sciences with rapid, on-demand microfluidic solutions, addressing crucial supply chain gaps and accelerating research and development. With its new MV-2 microvalve, Parallel Fluidics empowers researchers to perform microfluidic-based diagnostics and treatments directly at points of care. This move is particularly impactful as more sectors—ranging from diagnostics to IVF—look to leverage microfluidics for precision, scalability, and cost-efficiency in their innovations. As the global microfluidics market continues its significant growth trajectory, Parallel Fluidics’ accelerated timelines and reduction of engineering complexities could make it a major enabler in the next wave of biomedical breakthroughs.
